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Recombinant human growth hormone post-renal transplanta- was recognized more than a century ago [1]. Almost 40
tion in children: A randomized controlled study of the NAPRTCS. years ago at the beginning of the clinical transplantation
Background. Growth retardation persists in renal allograft
era one observer urged caution at those advocating end-recipients despite successful transplantation. The etiology is
stage renal disease (ESRD) care for children with CRImulti-factorial including the adverse effects of corticosteroids,
suboptimal allograft function, and perturbations of the GH/GF because of the concern “that successful transplantation
axis. Recombinant human growth hormone (rhGH) has been would result in a functioning kidney being housed in a
effective in improving growth velocity; however, allograft dys-
dwarf” [2].function has been reported. Therefore, a randomized con-
Successful renal transplantation is currently consid-trolled study was undertaken.
Methods. Sixty-eight growth retarded pediatric renal allo- ered the optimal therapeutic modality for infants, chil-
graft recipients were enrolled in a one-year randomized con- dren and adolescents with ESRD. A parameter for the
trolled study to determine the efficacy and safety of rhGH. A
long-term success of the procedure is the attainment ofprotocol biopsy was performed prior to enrollment.
targeted (genetic potential) adult height. Since the incep-Results. After one year, the delta SDS (standardized height)
was 0.49  0.10 in the treatment group (N  30) compared tion of the North American Pediatric Renal Transplant
to 0.10  0.08 in the control group (N  22; P  0.001). Cooperative Study (NAPRTCS) in 1987, it has been doc-
During the first year, there were no rejection episodes in the
umented in successive annual reports that growth retar-treatment group and three in the control group. After the first
dation persists despite successful transplantation [3–5].year, when all recipients were receiving rhGH, there were three
patients in the treatment group and two patients in the control Recipients who receive an allograft prior to age 6 years
group who experienced an acute rejection episode. Prior to may manifest an acceleration in growth velocity (catch-upenrollment, more than one acute rejection episode was pre-
growth) during the initial three to four years post-trans-dictive of a subsequent rejection following enrollment. There
plant; however, the majority of the pediatric allograftwas no difference in adverse events between the two groups.
Conclusion. In conclusion, rhGH is effective in improving recipients who are more than 6 years of age at the time
the growth velocity of pediatric renal allograft recipients and of transplant not only fail to demonstrate any catch-upis not associated with an increase in adverse events.
growth but actually manifest a negative change (delta) in
standardized height (z-score) following transplantation.
Multiple factors have been implicated for the failureGrowth retardation has been an onerous facet of
to achieve normal or accelerated growth following trans-chronic renal insufficiency (CRI) since the association
plantation, with perturbations of the growth hormone
(GH)/insulin-like growth factor (IGF) axis resulting1 North American Pediatric Renal Transplant Cooperative Study; a list
of participants and participating centers is in the Appendix. from corticosteroid therapy [6] and/or suboptimal allo-
† Deceased. graft function [7] playing a pivotal role.
Case reports [8, 9], open label studies [10–25] andKey words: growth retardation, children, renal transplantation, acute
rejection, chronic renal insufficiency, kidney graft. three controlled studies [26–28] have documented the
short-term efficacy of recombinant human growth hor-Received for publication November 14, 2001
mone (rhGH) in improving the growth velocity of growthand in revised form February 15, 2002
Accepted for publication March 22, 2002 retarded renal allograft recipients; however, the safety
of rhGH has been questioned with reports of acute rejec- 2002 by the International Society of Nephrology
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tion episodes [8, 9, 22] and accelerated decline in renal for a malignancy within one year, recipients with clinical
function in recipients manifesting chronic rejection [16, 17]. diabetes mellitus requiring active treatment, recipients
The latter is particularly important since those recipients with gonadotropin deficiency currently receiving estro-
with impaired allograft function may manifest significant gen/androgen therapy; recipients with deformities obvi-
growth retardation and therefore be the optimal candi- ating accurate height measurements, and recipients re-
dates for rhGH treatment. ceiving any other investigational drug within six months
To determine the impact of rhGH on graft function and of the study.
potentially delineate adverse risk factors, the NAPRTCS
undertook a multicenter, randomized controlled study Other medications
of the use of rhGH in growth-retarded renal allograft Prednisone dose0.15 mg/kg/day or0.25 mg/kg/day
recipients. administered q.o.d. with no significant change in any
immunosuppressive drug therapy for at least six months
except for adjustments secondary to changes in weightMETHODS
and fluctuations in blood/serum drug levels. Center-spe-Study subjects
cific immunosuppressive therapy was acceptable, and
Between December 1996 and June 2000, 68 renal allo-
when clinically indicated, additional medications weregraft recipients from 18 NAPRTCS participating centers
prescribed at the discretion of the center.(Appendix) were randomized to either a treatment (N
39) or control (N  29) group. The treatment group Informed consent
received 0.05 mg/kg/day of rhGH (Nutropin; Genentech,
The protocol was approved by the Institutional Re-Inc., So. San Francisco, CA, USA) daily for one year.
view Board at each participating center. Informed con-The control group received no treatment for one year
sent was obtained from the parent or guardian. Assentand then was offered rhGH treatment. Both groups were
was obtained from the patient when age appropriate.followed for a total of 30 months of rhGH treatment. No
follow-up information was obtained from four patients
Randomization(2 treated and 2 control) who were immediately with-
Upon enrollment each patient underwent a biopsy ofdrawn following enrollment and did not initiate any
the renal allograft that was processed at the center (andtreatment and one patient who was enrolled immediately
prior to discontinuation of the protocol and therefore interpreted at the center at the discretion of the investi-
the follow-up period was limited. Inability to achieve gator) and then forwarded to one of the authors (A.H.C.)
satisfactory site indemnification was the primary reason for retrospective interpretation utilizing the revised Banff
for withdrawal. criteria [22].
Therefore, follow-up data are available from 63 pa- If the center interpretation indicated the presence of
tients (36 treated and 27 controls). During the first year acute rejection the patient could receive treatment but
of the study, an additional ten patients were withdrawn could not be randomized for an additional six months
(5 treated and 5 controls). The reasons for withdrawal following an additional biopsy. This circumstance did
were as follows: treatment – participant choice (2), post- not evolve in any patient.
transplant lymphoproliferative disease (PTLD), diabetes Randomization into the treatment or control group
mellitus, gastrointestinal complications; control – non- was performed at the data coordinating center (Emmes
compliance (2), PTLD, physician request, rejection. Corp., Potomac, MD, USA) after stratifying for site and
rejection history.Inclusion/exclusion criteria
To be included in the protocol, patients must have Clinical studies
been at least one year post-transplantation, had a height
Prior to randomization the following baseline clinicaldeficit of 2 SDS (standard deviation score) or more, a
data were obtained: age, sex, race, Tanner stage, numberbone age 16 years for boys and15 years for girls, no
of prior rejection episodes, primary diagnosis, donorprior receipt of rhGH following the current transplant,
source, number of prior transplants, months post-trans-and no clinical rejection episodes requiring adjustments
plant, serum creatinine level, bone age, height, predni-in immunosuppressive therapy for more than six months
sone dose, and other immunosuppressive drug therapy.prior to enrollment.
At subsequent three month intervals the serum creati-Patients excluded from this study were those included
nine level, height, prednisone dose, number of subse-in other NAPRTCS protocols, recipients with evidence
quent rejection episodes and adverse events were ob-of a specific cause for the growth retardation other than
tained until 42 months from entry into the study. A bonethose implicated in renal allograft recipients, recipients
with active malignancy or those who had been treated age was obtained annually.
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Table 2. Baseline characteristics of post-transplantTable 1. Baseline characteristics of post-transplant
growth study participants growth study participants
Control TreatmentControl (N  27) Treatment (N  36)
(N  27) (N  36) P value
Sex
Male 25 29 Months post-transplant 58.97.9 62.14.7 0.22
Serum creatinine mg/dL 1.20.08 1.30.08 0.53Female 2 7
Race Calculated clearance 67.44.1 57.82.8 0.13
Bone agea 10.10.6 8.80.5 0.07White 14 23
Black 3 4 Height cm 131.63.5 124.82.0 0.03
Standardized height z score 2.960.18 2.950.16 0.96Hispanic 7 9
Other 3 0 Prednisone dosea
mg 5.60.55 5.70.44 0.99Age
5 1 1 mg/kg 0.160.01 0.190.02 0.91
6–10 6 13 Data are meanSE.
11–15 16 22 a Note: bone age sample sizes are 22 and 33, prednisone dose sample sizes are
16 4 0 21 and 34
Tanner stage
1 14 26
2 6 8
3 7 2 Table 3. Therapy at entry into post-transplant growth study
Rejections
0 18 16 Therapy Control (N  22) Treatment (N  34)
1 6 13
Cyclosporine 20 271 3 7
Tacrolimus 2 6Steroids
Mycophenolate 10 16Alternate 9 8
Azathioprine 8 17Daily 17 28
Prednisone 21 34None 1 0
Diagnosis There was no significant difference by immunosuppressive treatment between
Obstructive aplasia 13 16 the 2 groups.
FSGS 3 4
Cystinosis 4 2
Other 7 14
Donor source
of prior rejection episodes, type of corticosteroid treat-Living 15 25
Cadaver 12 11 ment, diagnosis, donor source and transplant number
Transplant for 27 control and 36 treatment patients at baseline are
1 25 34
shown in Table 1. The mean  SE months post-trans-1 2 2
plant, serum creatinine level, bone age, height and pred-There was no significant difference in any parameter between the 2 groups.
nisone dose of the 27 control and 36 treatment patients
at baseline are shown in Table 2. Immunosuppressive
therapy for 22 control and 34 treatment patients at entry
Statistical analysis are shown in Table 3. The dosage of azathioprine or
mycophenolate mofetil (MMF) in the treatment and con-This study examined changes in growth parameters,
serum creatinine levels and cumulative adverse experi- trol groups was not significantly different.
ences including rejection episodes after a year of obser-
Biopsy datavation or treatment with rhGH. One year scores and
changes in score were compared with the Wilcoxon sta- The biopsy findings were categorized and graded ac-
cording to the Banff 97 schema (Table 4). The majortistic and linear models that were constructed for covari-
ate adjusted comparisons. Growth velocity is presented abnormalities were of a chronic nature and, wherever
possible, were specifically designated rather than diag-as cm/month, and each calculation accumulated the ob-
served growth throughout the specified follow-up period, nosing the lesions as “chronic transplant nephropathy.”
Thus, in the case of chronic cyclosporine (calcineurinwhich was then normalized to a 30-day period. P values
are presented as two-tailed. inhibitor) toxicity, the constellation of patchy/striped tu-
bular atrophy and interstitial fibrosis with little or no
interstitial lymphocytic infiltration, arteriolar wall thick-
RESULTS
ening because of muscular hypertrophy often with insu-
Patient data dative lesions (hyalinosis), juxtaglomerular apparatus
enlargement and glomerular ischemia, were consideredFour patients (2 control and 2 treatment) were imme-
diately withdrawn from the study primarily because of virtually diagnostic [29–31]. Chronic rejection was diag-
nosed in the face of tubular atrophy with interstitialissues surrounding site indemnification and, therefore,
follow up was available on 63 patients. The sex, race, fibrosis with or without lymphocytic infiltration, arterial
intimal and/or medial fibrosis, and glomerular lesionsage according to four age groups, Tanner stage, number
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Table 4. Baseline biopsy data were withdrawn (5 from each group) during the first year
of the study and an additional patient in the treatmentBiopsy lesion Number
group failed to reach the 12-month height measurement1. Chronic nephropathy (not otherwise modified),
grade I (mild) 31 time interval. The reasons for patient withdrawal during
2. Chronic nephropathy (not otherwise modified), the first year in the treatment group were: patient/family
grade II (moderate) 6
choice (N 2), PTLD, diabetes mellitus, and gastrointes-3. Chronic nephropathy highly consistent with chronic
cyclosporine toxicity (grade I) 9 tinal complications. In the control group the reasons
4. Chronic nephropathy (chronic rejection) were: non-compliance/rejection (N 2), PTLD, patient/grade I 4
family choice and physician request.grade II 2
5. Chronic nephropathy, grade I with coexisting acute The growth velocity, height SDS, delta height SDS
rejection IA (4 bxs, 3 patients) 3 and delta height of the two groups of patients during6. Chronic nephropathy, grade I with
the initial 12 months of the study are shown in Figureglomerulonephritis (mesangial) 1
7. Chronic nephropathy with possible 1. In each parameter there was a statistically significant
glomerulonephritis (grade I) 1 difference between the treatment and control group.8. Inadequate 5
After 12 months the control group was offered treat-9. Waiveda 3
10. Not done/attemptedb 3 ment with rhGH. The data in Figure 2 demonstrate a
a Discretionary waiver by the principal investigator similar response to rhGH in the control group following
b Adequate biopsy material not obtained
one year of rhGH treatment.
Of the 27 patients in the control group, 17 were receiv-
ing daily corticosteroid treatment (DT) and 10 were re-
ceiving alternate day corticosteroid treatment (ADT).(chronic transplant glomerulopathy) consisting of a vari-
In the treatment group, 28 were receiving DT and 8able increase in mesangial matrix and cellularity, double
ADT at randomization. The mean 	  SE SDS at onecontoured capillary walls, and infrequently mesangio-
year in the control group for the DT and ADT groupslysis and microaneurysms. As the specimens were evalu-
was 0.05  0.10 and 0.22  0.16, respectively, and forated only by light microscopy, more detailed observa-
the treatment group 0.46  0.11 and  0.59  0.3,tions to assess for ultrastructural changes of glomeruli
respectively.and interstitium could not be done. Any other glomeru-
lar lesions possibly indicative of recurrent or de novo
Allograft functiondisease also could not be further delineated. Further-
The serum creatinine levels at baseline and at threemore, as a baseline biopsy at the time of transplantation
month intervals during the initial 12 month period arewas not available, it was not possible to be certain that
shown in Figure 3. There was no significant differencesome of the chronic changes were not of donor origin.
between the serum creatinine level in the two groups atThe changes were scored and categorized using the
any time point.Banff 97 schema [29]. In particular, the chronic changes
were quantitated and graded based primarily upon the
Rejection episodespercentage involvement of tubular atrophy and intersti-
During the first year of the study there were no rejec-tial fibrosis. For acute changes, the criteria for acute
tion episodes in the treatment group and three (atrejection were also used. Since this study was initiated
months 3, 4 and 10) in the control group. After the firstprior to the development of the Banff 97 classification,
year, three patients in the treatment group had rejectionour initial evaluation was done following the system de-
episodes at months 14, 15 and 16, while two patients invised by the Cooperative Clinical Trials in Transplanta-
the control group initially had rejection episodes (onetion [32], which was changed to the Banff criteria.
patient at month 15 and one patient at months 21, 24
Growth and 27). All of the latter occurred following initiation
of rhGH after 12 months in the control group. No biopsyThe mean SE SDS (standardized height) at baseline
material was submitted on the patients identified as hav-was 2.95  0.16 for the treatment group (N  36) and
ing a rejection episode.2.96  0.18 for the control group (N  27). At 12
Of the three patients in the treatment group who hadmonths the mean  SE was 2.58  0.19 for the treat-
rejection episodes after the first year, one had one priorment (N  30) and 2.99  0.17 for the control (N 
rejection episode and two had two prior rejection epi-22) group. The delta SDS was 0.49  0.10 for the
sodes. Of the five patients in the control group who hadtreatment and 0.10  0.08 for the control group at 12
months (P  0.001). Growth data were available for rejection episodes, three had no prior rejection episodes
and two had two prior rejection episodes. Thus, 4 of 10evaluation at one year in only 30 patients in the treatment
group and 22 patients in the control because 10 patients (40%) with 1 rejection episode prior to randomization
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Fig. 1. One-year study results according to
treatment group. Data are means  SE. Sym-
bols are: (dashed line) rhGH-treated with
Neutropin; (solid line) controls. (A) Growth
velocity (P  0.001). (B) Height SDS (stan-
dardized height score; P 0.03). (C ) Changes
in height SDS (P  0.001). (D) Changes in
height (P  0.001).
Fig. 2. Change in height according to treatment group. Symbols are: Fig. 3. Serum creatinine values over time. Symbols are: (dashed line)
(dashed line) rhGH-treated with Neutropin; (solid line) controls. rhGH-treated with Neutropin; (solid line) controls. Data are mean 
Whiskers denote the SE. SE, P  NS.
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Table 5. Adverse events recurrence. The patient in the control group who devel-
oped hyperglycemia after the first year following initia-Control Treatment
Year 1 (N  5) (N  7) tion of rhGH was withdrawn from the study.
PTLDa (1) PTLD (1) The patient with a headache and normal CSF pressure
ICHb (1) Headache (normal CSF) (1) in the treatment group was symptomatic at 7 months
Infection (2) Diabetes mellitus (1)
after randomization and subsequently withdrew bySeptic arthritis (1) Infection (2)
TIAc (1) choice at 15 months after initiation of the study. The
Genu valgum (1) patient in the control group developed ICH at one year
After 1 year (N  5) (N  1) following randomization and subsequently withdrew
Seizures (1) Hodgkin’s disease (1) without having initiated rhGH treatment.
Elevated serum (at 36 months)
creatinine (2)
Hyperglycemia (1)
DISCUSSIONEsophogeal
bleeding (1) The efficacy of rhGH in improving the growth velocity
a Post-transplant lymphoproliferative disease in renal allograft recipients had been demonstrated in
b Intracranial hypertension
multiple open label studies [10–25] over the past decadec Transient ischemic attack: Left sided numbness, weakness and vomiting asso-
ciated with a serum potassium level of 1.9 mEq/L, which resolved completely when comparing growth velocity during the year prior
with correction of hypokalemia
to rhGH treatment to either one, two or three years of
rhGH treatment. This has been shown in both prepuber-
tal and pubertal recipients [21, 23]. In pubertal recipients,
initiation of rhGH treatment during the latter stages ofexperienced a rejection during the trial versus only 4 of
puberty also has been shown to be efficacious [21].53 (7.5%) with zero or 1 prior rejection (P  0.02).
In three previous controlled studies efficacy has also
Allograft failures been uniformly demonstrated. Hokken-Koelega et al,
in a 1994 six-month placebo-controlled crossover study,There were no graft failures during the first year in
noted that rhGH induced an increment in growth veloc-either group. Subsequently, two patients in the treatment
ity that exceeded that of the placebo by 2.9 cm/6 monthsgroup lost their grafts consequent to chronic rejection
(P  0.0001) [26]. Maxwell and Rees reported a two-at 24 and 36 months and a patient in the control group
year randomized controlled study in 1998 of 15 prepuber-lost a graft consequent to non-compliance at 27 months.
tal and 7 pubertal recipients [27]. During the first yearThe latter patient had three acute rejection episodes in
six prepubertal and three pubertal recipients were thethe six months prior to graft failure.
control group. The growth velocity in the treatment and
Adverse events control groups was 8.1  0.9 versus 3.7  0.6 cm/year
in the prepubertal recipients and 10.1 0.6 versus 3.9 During the first year of the study there were five ad-
verse events in four patients in the control group and 1.3 cm/year in the pubertal recipients, demonstrating
an improvement in growth velocity with rhGH in bothseven adverse events in seven patients in the treatment
group. After one year there was one adverse event in one prepubertal and pubertal recipients compared to the
control group. Lastly, Guest et al, in their 1998 studypatient in the treatment group and five adverse events in
five patients in the control group who were then receiving randomized 90 recipients to either one year of rhGH
treatment or to a no treatment group that served asrhGH (Table 5).
The patient in the control group who developed PTLD controls [28]. The growth velocity was 7.7 cm/year in the
rhGH treated recipients compared 4.6 cm/year in thea few weeks after randomization has a functioning graft
at last report, 30 months after entry into the study. The control group (P  0.0001). The results of the current
randomized controlled study again validated the effec-patient in the treatment group who developed PTLD 9
months following randomization has a functioning graft tiveness of rhGH treatment of growth retarded recipi-
ents. The delta SDS after one year was 0.49  0.10 SE18 months after entry into the study.
The patient in the treatment group who developed in the rhGH treated group compared to 0.10  0.09
SE in the control group (P  0.001).Hodgkin’s disease after exiting at the end of the study,
36 months following randomization was still receiving Consequently, short (1 year) and moderate term (2 to
3 years) open label studies, and short-term (6 months torhGH. Following chemotherapy, the patient is in remis-
sion with a functioning graft. The patient in the treatment 1 year) controlled studies have demonstrated an im-
provement in growth velocity with rhGH treatment ofgroup who developed diabetes mellitus was withdrawn
from the study 18 days following randomization. Insulin renal allograft recipients. In pubertal recipients this has
been reflected in the attainment of target adult heighttreatment was discontinued within three months. Subse-
quent reintroduction of rhGH was not associated with in approximately one-third of the recipients [27].
Fine et al: rhGH post-renal transplantation in children694
In 1990 Tyden, Berg and Reinholt reported two recipi- pressed or more immunoreactive. However, the data do
not facilitate identification of rhGH treatment as precipi-ents who manifested biopsy-proven acute rejection epi-
sodes five and seven months, respectively, after initiating tating an acute rejection episode.
The protocol biopsies prior to the randomization uni-rhGH treatment at two and three years post-transplant,
respectively [8]. Treatment of the acute rejection episode formly indicated evidence of chronic allograft nephropa-
thy with occasional evidence of acute rejection. However,and subsequent discontinuation of rhGH was effective
in stabilizing allograft function. Subsequent open label there was no apparent connection between the protocol
biopsy findings and the clinical course following random-reports noted acute rejection episodes in approximately
25% of the recipients [11, 12]. An acute rise in the serum ization. Thus, our hypotheses that protocol biopsy find-
ings can identify recipients at risk for subsequent acutecreatinine level also was noted shortly after the initiation
of rhGH treatment that returned to normal values fol- rejection episodes following initiation of rhGH was not
confirmed.lowing discontinuation of rhGH [16, 22]. In the open
label studies attempts were made to delineate if the inci- Progressive deterioration of graft function has been
noted previously in recipients with chronic rejection re-dence of acute rejection episodes was increased by com-
paring the incidence prior to and following initiation of ceiving rhGH [16, 17]; in some instances allograft loss
ensued [20]. Although histologic evidence of chronic re-rhGH. In each report, no increase in the incidence was
noted [13, 19, 23]. Similarly, in the three controlled stud- jection was noted in a substantial number of the enroll-
ment protocol biopsies in the present report, the meanies no significant increase in the incidence of acute rejec-
tion episodes were noted in the treated compared to the serum creatinine level did not differ between baseline
and one year in either the treatment or control group.control group during the study period. Hokken-Koelega
et al did not observe any acute rejection episodes in Furthermore, there were no graft losses in either the
treatment or control group during the first year of thetheir six-month crossover study [26]. In the randomized
controlled trial of Maxwell and Rees, the presumed num- study. However, three grafts were subsequently lost: two
in the treatment group at 24 and 36 months followingber of rejection episodes during the first year of the trial
was 8/13 in the rhGH group compared to 5/9 in the randomization as a result of chronic rejection, and one
in the control group at 27 months consequent to non-control group (P  0.10) [27]. In the French multicenter
randomized controlled trial there was no significant dif- compliance. Since subsequent protocol biopsies were not
performed following enrollment, it is not possible toference in the incidence of biopsy proven acute rejection
episodes in the rhGH treated (9/44) compared to the determine any adverse impact of rhGH treatment on
the progression of chronic rejection.control group (4/46; P 0.11) [19]. However, the history
of acute rejection prior to rhGH treatment portended Adverse events potentially attributable to rhGH were
limited. Benign intracranial hypertension has been re-ominously for rejection following rhGH treatment; 6/17
recipients with two or more episodes prior to rhGH ported in patients receiving rhGH [33]. One patient in
the control group had benign intracranial hypertensiontreatment developed rejection following treatment com-
pared to 1/22 with zero or one prior acute rejection and one patient in the treatment group had a headache
with normal cerebrospinal fluid pressure. Hyperglycemiaepisode (P  0.01).
The incidence of acute rejection during the one year [34] and hyperinsulinemia [19] have been noted pre-
viously in recipients receiving rhGH. In the Frenchperiod of the present report was minimal; none in the
treatment group and three in the control group. After multicenter center, both the mean fasting glucose con-
centration and mean serum insulin values were signifi-the first year when all patients were receiving rhGH,
three patients in the treatment and two in the control cantly increased at one year compared to baseline values,
but were not different in the control and treatmentgroup who were then receiving rhGH had acute rejection
episodes. The lower incidence of acute rejection episodes groups [28]. One patient in the control group in the
present report developed hyperglycemia after one yearcompared to the other controlled studies could be related
to current treatment practices. following initiation of rhGH and one patient in the treat-
ment group developed diabetes mellitus. Discontinua-The data in this report confirm the information in the
French controlled study [28] that1 prior acute rejection tion of rhGH in the patient with diabetes mellitus led
to remission.episode is a risk factor for a subsequent episode following
initiation of rhGH; 4 of 8 (50%) patients with an acute One patient in each group developed PTLD; treat-
ment was discontinued in the patient receiving rhGH.rejection episode following initiation of rhGH had 1
prior acute rejection episodes, whereas, only 4 of 53 Both patients currently have a functioning graft. Since
the potential relationship between growth hormone(7.5%) with zero or 1 prior rejection episode had an
acute rejection episode following initiation of the study. treatment and the development of leukemia in patients
with growth hormone deficiency was raised more thanTherefore,1 prior acute rejection episode may identify
a patient population that is suboptimally immunosup- a decade ago [35], it has been a concern that treatment
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Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pedi-with rhGH of renal allograft recipients, who have an
atr Transplant 1:146–162, 1997
increased incidence of de novo malignancies [36], would 5. Benfield MR, McDonald R, Sullivan EK, et al: The 1997 Annual
Renal Transplantation in Children: Report of the North Americanlead to a further increase. The data in this and all previ-
Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pedi-ous reports have not substantiated this concern. How-
atr Transplant 2:152–167, 1999
ever, the recent report of renal cell carcinoma in two 6. Schaefer F, Veldhuis JD, Stanhope R, et al: The cooperative
study group on pubertal development in chronic renal failure.recipients who received rhGH indicates caution [37].
Alterations in growth hormone secretion and clearance in peripu-Surveillance is advisable when prescribing rhGH to im-
bertal boys with chronic renal failure and after renal transplanta-
prove growth velocity in pediatric solid organ transplant tion. J Clin Endocrinol Metab 78:1298–1306, 1994
7. Tejani A, Fine RN, Alexander S, et al: Factors predictive ofrecipients. Furthermore, after this study was completed
sustained growth in children after renal transplantation. J Pediatrone recipient who had been in the study and had received
122:397–402, 1993
rhGH for 2 years developed biopsy-confirmed Hodg- 8. Tyden G, Berg U, Reinholt F: Acute renal allograft rejection
after treatment with human growth hormone. Lancet 336:1455–kin’s disease. Discontinuation of rhGH and specific che-
1456, 1990motherapy has induced a remission (Susan Thomas, per-
9. Schwartz D, Warady BA: Cadaveric renal allograft rejection after
sonal communication). treatment with recombinant human growth hormone. J Pediatr
121:664–665, 1992In conclusion, a multicenter randomized controlled
10. Rees L, Rigden SPA, Ward G, Preece MA: Treatment of shortstudy demonstrated that rhGH significantly improves
stature in renal disease with recombinant human growth hormone.
growth velocity in growth-retarded renal allograft recipi- Arch Dis Child 65:856–860, 1990
11. Johansson G, Sietnieks A, Janssens F, et al: Recombinant humanents. Enrollment protocol biopsies demonstrated histo-
growth hormone treatment in short children with chronic renallogic evidence of chronic allograft nephropathy at the
disease, before transplantation or with functioning renal trans-
time of randomization. No acute rejection episodes were plants: An interim report on five European studies. Acta Paediatr
Scand (Suppl 370):36–42, 1990noted in the treatment group during the initial year of
12. Tonshoff B, Dietz M, Haffner D, et al: Effects of two years ofthe study. The data would seem to indicate that rhGH
growth hormone treatment in short children with renal disease.
is safe and effective in renal allograft recipients. Acta Paediatr Scand (Suppl 379):33–41, 1991
13. Fine RN, Yadin O, Nelson PA, et al: Recombinant human growth
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